TCT 577: Impact of Left Ventricular Dysfunction on the Outcome of Patients Undergoing Microaxial Flow Pump-Supported High-Risk Percutaneous Coronary Intervention

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Edwards Lifesciences; Abiomed; Boston Scientific Corporation; AstraZenca; Bristol-Myers Squibb; Bayer AG; Sanofi-Aventis; Medtronic; Novartis